Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study-Reference-Cited by-同舟云学术

Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study

Published:2018-11-08 Issue:4 Volume:34 Page:698-710
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Imaizumi Satoshi^ORCID, ,Shiga Yuhei,Ogawa Masahiro,Sako Hideto,Nagata Yoshihisa,Matsunaga Akira,Shirotani Tetsuro,Hoshino Fumihiro,Yahiro Eiji,Uehara Yuko,Morito Natsumi,Tanigawa Hiroyuki,Shimono Dai,Fukushima Mikio,Sugihara Hidekazu,Norimatsu Kenji,Kusumoto Takaaki,Saku Keijiro,Miura Shin-ichiro

Funder

Dainippon Sumitomo Pharma

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00380-018-1286-2.pdf

Reference39 articles.

1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419

2. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444

3. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR (2011) Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension 57:891–897